AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01112943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture on predefined points for 20min once a week over seven weeks
Study NCT01112943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: a seven week pulmonary rehabilitation course
Study NCT01967524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A + ropivacaïne
Description: D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
Study NCT01967524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaïne
Description: D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36).
Study NCT02658344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection
Study NCT02658344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution (Sodium chloride 9mg/ml), 1 time injection
Study NCT01112943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
Study NCT00605865 — intervention group
Intervention type: DRUG
Intervention: Sertraline hydrochloride
Description: J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration.
Study NCT05314114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary surgery
Description: No axillary surgery
Study NCT00891371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: Autogel 120mg
Study NCT01706874 — intervention group
Intervention type: OTHER
Intervention: Periodontal prophylaxis
Description: Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
Study NCT02609412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static compression of LMTRP
Description: Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
Study NCT02609412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic self-myofascial release of calf
Description: Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
Study NCT02609412 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser acupuncture of LMTRP
Description: Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
Study NCT02799238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALECSAT
Description: 3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
Study NCT00661869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Program
Description: 36 weeks of educational and supportive interventions
Study NCT02193828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: Single injection into nodule
Study NCT02193828 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection into nodule
Study NCT03308162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral experiential group therapy
Description: The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
Study NCT05551091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycomacropeptide (GMP)
Description: For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
Study NCT04231955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: numerical rating scale
Description: patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
Study NCT04231955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual analogue scale
Description: Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level.
Study NCT04231955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: color analogue scale
Description: Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level.
Study NCT04231955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: faces rating scale
Description: Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level.
Study NCT01771211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
Study NCT01771211 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
Study NCT01677624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E7040
Description: E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Study NCT04238884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole preemptive genotyping strategy
Description: The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
Study NCT04238884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole clinical practice
Description: The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
Study NCT01324934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG-Fresenius S
Description: Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids).
Study NCT05378022 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax
Description: In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
Study NCT05378022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study NCT03978104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Okara biscuits
Description: Consumption of okara-enriched biscuits together with habitual diet.
Study NCT03978104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-okara biscuits
Description: Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
Study NCT03978104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control biscuits
Description: Consumption of control biscuits together with habitual diet.
Study NCT02517853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Study NCT02517853 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham posterior tibial nerve stimulation
Study NCT05238987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: Single dose of ferrous sulphate (120 mg of elemental iron)
Study NCT02963896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin
Description: intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
Study NCT01005056 — intervention group
Intervention type: DRUG
Intervention: Ethinylestradiol + Desogestrel
Description: All participants receive Marvelon® according to the approved dosage and administration method.
Study NCT01481909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rupatadin
Description: 20 mg, 28 days over 60 days
Study NCT02158819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Visionaire
Description: Patient Specific Instrumentation
Study NCT01393067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-expandable plastic stent (plastic endoprosthesis)
Description: plastic stent (plastic endoprosthesis)
Study NCT01393067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered self-expandable metal stent (cSEMS)
Description: Removable, covered self-expandable metal stent (cSEMS)
Study NCT04577924 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital.
Study NCT01828554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage.
Study NCT01651767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=suspension, route=oral.
Study NCT01651767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
Study NCT02753738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Tablet 10mg, 21 days
Study NCT02753738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 21 days
Study NCT02753738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3xMR scan (fMRI, DTI, strucutral MRI)
Description: 3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
Study NCT02753738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3xMR scan (fMRI, DTI, strucutral MRI)
Description: 3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
Study NCT02753738 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Association learning paradigm
Description: 21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
Study NCT02753738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Association learning paradigm
Description: 21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
Study NCT02799238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 5 days/week for 6 weeks
Study NCT02799238 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy 5 days/week for 6 weeks
Study NCT02799238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
Study NCT02799238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
Study NCT03785535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
Study NCT03785535 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vibrotactile stimulation
Description: The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
Study NCT04095949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artichokes
Description: Approximately 200 g of cooked artichokes
Study NCT05562908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicled
Description: Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
Study NCT05562908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical skeletonised
Description: Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
Study NCT05562908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thunderbeat skeletonised
Description: Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
Study NCT00658931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug treatment with Cymbalta
Description: Drug treatment with Cymbalta
Study NCT02872792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early mobilisation with cyclo ergometer
Description: Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
Study NCT02872792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
Study NCT02872792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
Study NCT00614809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: gefitinib 250mg qd until disease progression or unacceptable toxicity.
Study NCT00262041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, adjuvanted
Study NCT00262041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, unadjuvanted
Study NCT00262041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY polysaccharide vaccine
Study NCT03831763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ColdZyme
Description: ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap.
Study NCT03012672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT03012672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03012672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given SC
Study NCT03012672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT03012672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03012672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05717855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Displaying optic chiasm for screening septooptic dysplasia
Description: Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
Study NCT01332578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Present in both test and active comparator
Study NCT01332578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Present in both test and active comparator